News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

AI Semi Ltd. Nominate Dr Randy Lieberman As President And Chief Scientist Officer

10/19/2005 5:12:12 PM

HEDERA, Israel, September 19 /PRNewswire/ -- AI Semi Ltd. has announced that Dr Randy A. Lieberman (MD) has been nominated by the company board of directors as the President and Chief Scientist Officer (CSO) of the company.

Dr. Lieberman is the Director of Cardiac Electrophysiology at Harper University Hospital in Detroit, USA and Assistant Professor of Medicine at Wayne State University School of Medicine. Dr. Lieberman specializes in the diagnosis and treatment of cardiac rhythm disorders (arrhythmias) and heart failure and has a special interest in the treatment of atrial fibrillation and heart failure. He is a world-recognized expert in cardiac ablation, Cardiac Implantable Electronic Devices (CIEDs), Cardiac Resynchronization Therapy (CRT) and the precise placement of cardiac pacing electrodes within the heart.

A sought-after lecturer and educator, Dr. Lieberman travels the world teaching the latest cardiac pacemaker techniques. As a researcher, he has helped develop new techniques and technologies that are changing the way physicians treat arrhythmias and heart failure. He has published many studies, abstracts and book chapters.

CRT And Beyond

AI Semi was founded in November 2003, as part of Yozmot Incubator, Israel Chief Scientist Technological Incubators program. The company develops a system solution for Adaptive Cardiac Resynchronization Therapy (aCRT) devices with dynamic optimization of pacing intervals according to hemodynamic sensors, based on the company proprietary neural network processor. AI Semi has developed a novel technology that allows CRT manufacturers to offer patients an auto-programmable and auto-adjustable CRT device. Its system solution enables the replacement of the manual programming process with an automated optimization process based on a neural network processor. AV delay and V-V interval are changed dynamically through an automated closed-loop optimization process. AI Semi's device learns individual patterns and improves over time to optimize patient's cardiac output and quality of life.

The neural network processor performs reinforcement learning combined with a pattern recognition scheme performed with extremely low dynamic power dissipation. AI Semi's micro-controller and neural network processor master-slave hybrid architecture is a breakthrough for a life supporting medical device based on neural network technology. An external adaptive CRT prototype is being tested in acute animal experiment (Q3/Q4 2005).

The company has five pending patents that suggest system solutions also for dual chamber pacemakers, for ventriclular pacing during atrial fibrillation and for cardiac stimulation with Hemodynamic GuardTM (Cardiac stimulation with hemodynamic sensor guard algorithm) which may expand the company addressable market beyond the CRT devices to all implanted pacemakers and defibrillators.

AI Semi's team of management, board of directors, and scientific advisory board includes a seasoned group of experts such as Dr. Rami Rom, CEO, Dr. Randy A. Lieberman (MD), President and CSO, Harper University Hospital, Detroit, Dr. Michael Glikson (MD), Sheba Hospital, Tel-Aviv, Dr. Jacob Erel (MD), Meir Hospital, Kfar-Saba, Prof. David L. Hayes (MD), Mayo Clinic, Rochester, Juan Carlos Castrosin, Next Medical, Madrid, Dr Kobi Rozenblum, Brain Research Center, Haifa University, Prof. Ofer Binah, Rappaport Institute, Technion, Haifa and Dr. Ran Ginosar, Electrical Engineering, Technion, Haifa.

The Company seeks $1.5 Million to complete the development and testing of the external adaptive CRT prototype and to support a joint project with a pacemakers company for developing, testing and manufacturing an implanted adaptive CRT device.

Contact: AI Semi Ltd. Dr. Rami Rom, CEO Cell: +972-523-224091 Fax: +972-4-632-1392

AI Semi Ltd.

CONTACT: Contact: AI Semi Ltd., Dr. Rami Rom, CEO,, Cell:+972-523-224091, Fax: +972-4-632-1392

Read at

comments powered by Disqus